Form 4: Akero CSO Sells Shares After Option Exercise

Akero Therapeutics' Chief Scientific Officer, Timothy Rolph, sold a total of 12,500 shares of common stock on October 7, 2025, following the exercise of stock options.

Summary

• Timothy Rolph, Chief Scientific Officer of Akero Therapeutics, Inc. (AKRO), engaged in transactions on October 7, 2025.
• He exercised stock options to acquire 12,500 shares of common stock at an exercise price of $28.35 per share.
• Immediately following the exercise, he sold a total of 12,500 shares of common stock.
• The sales were executed in two batches: 11,463 shares at a weighted-average price of $46.013 (ranging from $45.545 to $46.54) and 1,037 shares at a weighted-average price of $46.822 (ranging from $46.57 to $47.10).
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan established on August 12, 2024.
• Following these transactions, Timothy Rolph beneficially owns 166,571 shares of common stock directly and 49,945 stock options.

Sentiment

Score: 5

Explanation: The Chief Scientific Officer exercised vested stock options and immediately sold the acquired shares as part of a pre-arranged 10b5-1 trading plan. This is a common practice for executives to manage personal finances and diversify holdings. While a sale reduces insider ownership, the pre-planned nature mitigates concerns about opportunistic selling, and the officer retains substantial equity.

Positives

• The exercise of options indicates a profit for the officer, as the sale prices ($46.013 and $46.822) were significantly higher than the exercise price ($28.35).
• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which suggests the sales were not based on new, non-public information.

Negatives

• A Chief Scientific Officer selling shares could be perceived negatively by some investors, as it reduces their direct equity stake in the company.

Risks

• No specific risks to the company's operations or financial health are disclosed in this Form 4 filing.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This Form 4 filing details an individual insider transaction and does not provide broader industry context or analysis.

Stakeholder Impact

• Shareholders may view the sale as a slight reduction in insider confidence, though the pre-planned nature under Rule 10b5-1 mitigates this concern. The officer still holds a significant number of shares and options.

Key Dates

Recommendation

The Form 4 filing details a routine, pre-planned transaction by a company executive involving the exercise of vested stock options and subsequent sale of shares. This is a common practice for executives to manage personal liquidity and diversify their portfolios. While the sale reduces the officer's direct shareholding, the transaction was executed under a Rule 10b5-1 plan, indicating it was not based on new, non-public information. The officer retains a substantial beneficial ownership in the company. Without additional company-specific news or broader market context, this single transaction does not provide sufficient grounds for a strong buy or sell recommendation, thus a 'hold' is appropriate.

Keywords

Akero Therapeutics, AKRO, Form 4, Insider Trading, Stock Options, Share Sale, Timothy Rolph, Chief Scientific Officer, 10b5-1 Plan